Connect Sign InMolecular Testing and Cytopathology: Downsizing Precision Medicine but not Precision
Cytology is said to be the art of doing more with less. As minimally invasive tissue procurement techniques evolve and as there is an ever-increasing number of clinically relevant analytes in molecular oncology, this has never been more the case than in this era of precision medicine. There is the need for the cytopathologist, and the anatomic pathologist in general, to be able to understand indications for molecular testing, advantages and limitations of different testing platforms and to develop strategies in order to be able to provide quantitatively and qualitatively adequate specimen, without compromising diagnostic ancillary testing.
Dr. Deftereos is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD from the University of Bari Aldo Moro in Italy. Prior to his pathology training, Dr. Deftereos completed a research fellowship focusing on HPV and gynecological malignancies at the University of Washington in Seattle, Washington. He then completed a residency in anatomic and clinical pathology at Allegheny General Hospital in Pittsburgh, Pennsylvania, followed by consecutive clinical fellowships in cytopathology and molecular genetic pathology at the University of Washington. Dr. Deftereos provides service in the areas of molecular oncology and cytopathology. His research interests include epigenetics of solid tumors and minimally invasive precision diagnostics, with emphasis on the use of molecular testing in cytopathology of solid tumors.
